Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
However, as new offerings enter the FDA approval pipeline to meet demand, one constant remains: Per the FDA labeled indication for Saxenda and Wegovy (two GLP-1s approved for obesity treatment), both medications should be prescribed in conjunction with a lower calorie diet and increased physical activity, i.e
Cardiovascular death: 2.5% (Wegovy) vs 3.0% (placebo) Heart failure composite: 3.4% vs 4.1% All-cause death: 4.3% vs 5.2% A related study determined that 100 people with obesity would need to be treated for three years to prevent one major cardiovascular event
Staying Safe While on GLP-1 Therapy GLP-1 medications like Semaglutide and Tirzepatide offer significant benefits, especially for weight loss and blood sugar management
GLP-1 MEDICATIONS There are currently two classes of GLP-1 receptor agonists available for weight loss: semaglutide and tirzepatide
